Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. - Wikidata - wikimedia - TriplyDB

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

http://www.wikidata.org/entity/Q37988393

about

Idiopathic Inflammatory Myopathies: Clinical Approach and Management Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies Idiopathic inflammatory myopathies Rituximab in the treatment of inflammatory myopathies: a review Idiopathic inflammatory myopathies.Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review.An overview of polymyositis and dermatomyositis.Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study [co Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population.Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis Clinical heterogeneity and outcomes of antisynthetase syndrome.Diagnosis, pathogenesis and treatment of myositis: recent advances.The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.Current pharmacological treatment of idiopathic inflammatory myopathies.Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.Long-term follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors.Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years.Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease.Systemic Autoimmune Diseases.The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: The relation between the disease activity and the serum interleukin-6 level.Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease.Successful treatment with intravenous high-dose immunoglobulin for cardiomyopathy in dermatomyositis complicated with rapid progressive interstitial pneumonia.The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases.Anti-MDA5 Antibody-Positive Dermatomyositis Presenting with Cellulitis-Like Erythema on the Mandible as an Initial Symptom.Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment.

P2860

Q26744705-37AA500C-88AA-4050-B668-D74F8D0B013D Q26798023-712F3D55-DB0D-44E7-9FF0-4413E1F8AE71 Q27025125-3C703E24-6A6C-42CD-9E34-FBE9247373C2 Q28077745-7BEDFF6D-D408-4136-9454-BD35FECB99BE Q33924451-6E20FC8A-4900-4344-9633-DA5EBD4E0076 Q34526090-34FD510A-D4BD-44BC-A9A1-0AD0746B0AD9 Q34667765-3DB4F84F-AF04-48A7-9B93-7FE109F88BDF Q35107728-8CA6AD4F-5886-41EB-BC70-AC02719AF1D0 Q36015534-1219DD0F-67EF-4F5E-A21F-1275FA521A4B Q36692379-D31865BF-3C4C-419E-964F-85AE5AD65D2A Q37704772-EB639E9D-B175-44DF-B991-B905A5B11605 Q37706152-C108C3F4-869B-45DE-9F9C-AA38A14467B1 Q38116464-D55CF558-0E70-4071-A0C2-0F9F27BFC633 Q38131849-4DD71940-5EE2-4101-A662-FE3D0EE2083F Q38258248-2B678E09-F961-41BA-B511-44EC18CEA823 Q38607528-54024322-C07F-4618-B2B2-45FA4D36004A Q38680762-6A96DDAC-C192-4A38-B4B4-B728768E1920 Q38793513-FBAF01D5-83CE-4CF8-9999-23ECA24FB730 Q39147131-9D80DFFB-AAFC-4A89-B7AA-7EFF3D74E321 Q39776324-E244AAD3-919E-4BA2-8AD8-A8603023D7E6 Q40901486-B84B0E7D-E480-4424-B604-51AC80907707 Q41532897-97FF4C3E-6B7F-4821-89F1-67C66E8654E8 Q42147109-99A7EB8A-DAF5-4740-A15B-3437CC1F37AE Q42634230-60CFCFA3-0152-4E24-AE98-73176C34A944 Q45773557-AA7E96D3-7841-46F3-8D26-B507B3E3D6D7 Q46748760-12722E61-4E2F-4585-85C6-716B6E439E3F Q47659489-CF8249DD-33EB-453F-B0CB-0A78478EACCE Q47881134-5D7A7189-43C5-48B1-A877-AD11AFA86887 Q51280183-8629E9B5-8F12-4225-9FAA-646343FFBD88 Q51547408-21A0DAD4-DA7E-4391-BCBF-0625E240E116 Q51586236-20F6FEF1-C5CC-46AF-97ED-516F6E95E0CA Q51700184-30F02326-FE95-47B3-807D-D873B43A9B29 Q55256600-E880B3C6-4CCE-4A69-8F3B-67064ADEFB32 Q55361229-7FA1A646-8453-4EBA-BD39-63E9A4534789

P2860

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

http://www.wikidata.org/entity/Q37988393

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

@en

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

@nl

type

label

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

@en

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

@nl

prefLabel

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

@en

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

@nl

P1433

Q37988393-9305CC14-5086-4669-8AF6-BB11A3F18DB3

P1476

Q37988393-63C89D1B-3AAF-4F4D-A0CE-8B681EA794E4

P2093

Q37988393-89E0F57F-C455-4A23-B65B-89E70CDD7D08

Q37988393-BBAC0DB4-8555-43BB-81D5-DC8E60759585

Q37988393-C7CAFD02-4005-45D0-B862-73EAF68A827F

P2860

Q37988393-0686037F-7CE9-40F5-A2D9-963B4E7EA397

Q37988393-102F988B-937F-4A45-B17A-718A12F8905A

Q37988393-20236B67-7221-49BF-9DD5-551D6B659DAC

Q37988393-221C8EE7-224E-4A6C-9634-C8B11070A2A8

Q37988393-22A4C516-57C3-4C92-ADCC-CA862A3B42D5

Q37988393-25DF78F1-176C-4908-8030-2E330C272C91

Q37988393-28CA3F2E-8E83-4093-9EEC-A93AEC8DC94D

Q37988393-2937B45C-EB68-45B6-B7C5-94F35FBF03A8

Q37988393-2A5A6003-445C-4995-B0B1-DC487F68D72B

Q37988393-2FFF3733-DB7A-4D02-8036-5BF2EEDE5C47

P2888

Q37988393-133F3FEB-3353-4092-84DC-773C7DDD6F60

P304

Q37988393-488C2BAA-C86B-4178-A78F-B8BC6F60E408

P31

Q37988393-498CAB93-8E6F-4E72-9F44-8FD5A6960571

P356

Q37988393-867A21B7-A80F-41E0-9EE7-F4174D9A3832

P433

Q37988393-4578CCA5-6086-4092-AF07-3BFA9B2ED86E

P478

Q37988393-62995882-0C16-445C-89BC-A2C9FCFB1FA0

P577

Q37988393-11A23091-E717-42FC-8556-F5DFF97CD048

P5875

Q37988393-A664F3E9-9177-4468-8E4C-8EB6821199D8

P698

Q37988393-BD1D7AB5-3377-429F-A4A3-0B4446C6B7FB

P921

Q37988393-56CA8007-D696-44DA-B204-F57682A9C16E

P356

S11926-012-0246-6

P1433

Current Rheumatology Reports

P1476

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

@en

P2093

Ran Nakashima

http://www.w3.org/2001/XMLSchema#string

Tsuneyo Mimori

http://www.w3.org/2001/XMLSchema#string

Yuji Hosono

http://www.w3.org/2001/XMLSchema#string

P2860

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease.

Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.

Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia.

Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system.

Tacrolimus in refractory polymyositis with interstitial lung disease.

Opioid use by patients in an orthopedics spine clinic.

Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase.

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study

A randomized, pilot trial of etanercept in dermatomyositis.

P2888

s11926-012-0246-6

P304

264-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11926-012-0246-6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221863775

http://www.w3.org/2001/XMLSchema#string

P698

22367479

http://www.w3.org/2001/XMLSchema#string

P921